Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer

Table 1 Real-world studies of gemcitabine/nab-paclitaxel in the first-line setting[19-23]

Ref.	Location	Study design	Stage M1	n	Regimen	mOS in mo	Subgroup analysis	mPFS in mo	Remarks
Prager et al[19], 2021	Austria	Prospective cohort	100%	317	GnP	10.6/10.2	Age < 70/> 70	5.6/5.5	No difference in frequent toxicities
Blomstrand et al[20,21], 2019/2020	Sweden	Retrospective cohort	71%	75	GnP	10.9	Alb <3 7, age < 65 with shorter survival	5.2	Less hematotoxicity than MPACT
Ostwal et al[22], 2018	India	Retrospective cohort	83%	78	GnP	11.6		5.6	Grade III-IV toxicity 35%
Quinton et al[23], 2018	United Kingdom	Retrospective cohort	100%	74		8.4		-	Hematotoxicity similar to MPACT

GnP: Gemcitabine/Nab-paclitaxel; M1: Metastatic disease; mOS: Median overall survival; mPFS: Median progression-free survival.